Glycemic control in patients with type 2 diabetes was improved through a shared medical appointment program focusing on lifestyle education and behavior change.
Analysis of 77,462 family practice providers showed large regional differences in types of procedures performed, and significant differences in submitted charges and payments, across regions.
A decision-analytic model was used to estimate cost-effectiveness of adopting a 21-gene assay in treatment decisions for women with early-stage N (1-3)/ER HER2-negative breast cancer.
Four large Medicare Advantage insurers manage access to expensive physician-administered drugs with a combination of prior authorization, step therapy, and Part D formulary design.
High rates of health information technology use by physicians were only modestly associated with better knowledge of drug costs.
A discussion on meaningful measurement and driving greater value in healthcare, and the role of the National Quality Forum.
States offering pharmacists full immunization privileges have significantly higher vaccination uptake rates for pneumococcal disease and herpes zoster than states with restricted or no authorization.
Compared with traditional Medicare, relative resource use for those with diabetes or cardiovascular disease is lower in Medicare Advantage, while quality of care is higher.
This supplement showcases the winning papers from the PAN Challenge, which aimed to foster conversations about how to rein in out-of-pocket costs to eliminate barriers between patients and their critical medical treatments.
Developing alternative payment models for commercial populations in specialties such as oncology is rife with practical challenges. Leading payers and practices share lessons to date.
The mean 24-week cost per participant was $5416 for extended-release injectable naltrexone (57% detoxification, 37% medication, 6% provider/patient) and $4148 for buprenorphine-naloxone (64% detoxification, 12% medication, 24% provider/patient).
Neal Shore, MD, FACS, shares his final thoughts on the current landscape of clinical trials for both non-muscle-invasive bladder cancer and muscle-invasive bladder cancer, providing insights into the potential impact and future directions of these studies.
Implementing a claims-based algorithm and disease management program may be an effective strategy to reduce relapse and cost among patients with schizophrenia.
Routine preoperative MRSA screening of cardiac surgery patients could provide substantial economic value to third-party payers and hospitals under a wide range of circumstances.
This study shows automatic, practical, simple, and effective strategies designed in the laboratory, in consensus with requesting clinicians, to improve laboratory test appropriateness.
This editorial discusses the cost implication of bariatric surgery and whether or not return on investment analysis should be used to make coverage decisions.
Hybrid approaches allow for clinician input into case finding for care management, but training and monitoring is required to protect against unintentional biases.